39 results about "Mature cell" patented technology

The present invention relates to a modified stem cell and an ex vivo method for preparing defined mature cells from genetic programming of said modified stem cell which can be carried out in absence of certain growth factors, as well as a kit allowing to transform stem cells, and the different uses of the mature cells, for example for in vitro drug screening and toxicology or as cultivated meat. The genetic programming involves a molecular switch between two mutually exclusive programs of stem cell expansion and differentiation. The invention may be used for stem cells or other progenitors cells of any type, from any eukaryotic organism, but finds particular application in pluripotent stem cells from humans and livestock animals.

The invention discloses a culture method for improving proliferation and differentiation capacity of NK (Natural Killer) cells based on angelica sinensis-astragalus membranaceus exosomes, which comprises the following steps: firstly extracting exosomes in angelica sinensis and astragalus membranaceus, then adding the exosomes into an NK cell culture system according to a specific concentration, and regulating and controlling an NK cell signal channel by virtue of active ingredients carried by the exosomes so as to improve the proliferation and differentiation capacity of the NK cells. Therefore, the proliferation rate and differentiation maturity of the NK cells are remarkably improved. Experimental results show that compared with a traditional culture method, the proliferation multiple of the NK cells cultured through the method is increased by 28.99%-33.69%, the proportion of differentiated mature cells is increased by 15.91%-28.30%, and the cell killing activity is not remarkably reduced. The method can be widely applied to the field of immune cell treatment, provides a high-quality NK cell source for clinic, effectively solves the problems of slow cell proliferation rate, low differentiation maturity, easy activity reduction after large-scale culture and the like in traditional NK cell in-vitro culture, and has important clinical application value and industrialization prospect.

The present invention pertains to the technical field of biomedicine, and specifically relates to a gene delivery system and use thereof in the preparation of a tumor therapeutic drug. The present invention relates to a technical means for inducing differentiation of tumor cells into mature cells, which utilizes messenger ribonucleic acid to regulate the expression of HNF4α in tumor cells, inhibits the malignant phenotype of malignant solid tumor cells, and achieves the effect of treating malignant solid tumors, thereby being applied to a preparation method and use of a solid tumor drug.

Disclosed herein include methods, compositions, and kits suitable for use in cell therapy. In some embodiments, there are provided methods and compositions for differentiating stem cells into pancreatic beta cells capable of producing insulin.

A method of generating cells of the T cell lineage is provided that involves culturing a sample comprising stem cells or progenitor cells with an engineered Notch ligand conjugated to a suspension support and isolating cells of the T cell lineage. In one embodiment, the cells of the T-cell lineage are progenitor T cells or mature T cells. Compositions, kits and uses thereof are also provided.

Disclosed are methods for culturing coronavirus particles in early syncytiotrophoblasts (eSTBs). The derived eSTBs are mononucleated or bi-nucleated cells with high ACE2 expression and are not multi-n

An isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a B Cell Maturation Antigen (BCMA) polypeptide. The CAR preferably binds an epitope comprising one or more amino acids of residues 13 to 32 of the N-terminus of human BCMA. Also disclosed is a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic B cells, such as a disease of plasma cells, memory B cells and / or mature B cells, in particular multiple myeloma, non-Hodgkin's lymphoma or autoantibody-dependent autoimmune diseases.

The application belongs to the technical field of biological medicine and nanomaterials, and particularly relates to a kind of bionic nano drug delivery system, preparation method and application in eye immunotherapy.The application is with mesoporous SiO2 Nanomicrosphere as core, after protonation treatment, load sCD83, and coat mature DC cell membrane, form DCM@MSN / sCD83 nano drug delivery system.The preparation method of the application has high biocompatibility and simple operation, and the system can actively target mature DC after vitreous injection, release sCD83 and induce mature DC to transform into resistant DC, secrete IL-10 and TGF-β and other anti-inflammatory factors, inhibit STING path activation, reduce retinal inflammatory damage;At the same time, it can penetrate blood-ocular barrier into peripheral circulation, induce mature DC differentiation in neck lymph nodes and spleen and other immune organs, realize local and systemic synergistic immunoregulation, and can be used for preparing medicaments for treating experimental autoimmune uveitis.

A gene delivery system and applications thereof in the technical field of biological medicines that is particularly useful in the preparation of drugs for treatment of tumors are disclosed. The gene delivery system and applications relate to technology for inducing the differentiation of malignant tumor cells into mature cells, in which regulating the expression of HNF4 alpha protein in the malignant tumor cells using messenger ribonucleic acid, the malignant phenotype of the malignant solid tumor cells is inhibited, and the effective treatment of the malignant solid tumors is achieved. The gene delivery system and applications are therefore applicable to a method of preparing a drug for treating malignant solid tumors and to a method of treating a patient having a malignant solid tumor.

The present disclosure relates to compositions and methods for modulating signaling in a cell and / or for differentiating / maturing a cell. Compositions of this disclosure, as may be used in associated methods, may include first and second segments that are connected to one another. When used in methods to differentiate and / or mature immune cells, compositions of this disclosure advantageously increase frequency and yields of arising cells in comparison to conditions deploying only first or second segments separately, or both individually (not connected).

The current disclosure provides methods and compositions that provide for the insertion of transgenes in stem or progenitor cells without the deleterious effects to T cell differentiation by in vitro T cell differentiation methods. To accomplish this, the inventors have discovered that expression of the transgenes under the control of promoter regions, such as CD8a or CD8b, allows for the coordinated expression pattern that provides for both: 1) high expression of the transgene in mature T cells and 2) a coordinated level of expression of the transgene throughout the in vitro differentiation method that allows for the production of a population of mature T cells.

Provided are an induced NK cell, and a preparation method therefor and the use thereof. The method comprises mixing a CD34+ cell with a stromal cell, co-culturing the mixture to obtain an NK precursor cell, and subjecting the NK precursor cell to induction and amplification culture to obtain a mature NK cell, wherein the stromal cell comprises any one or a combination of at least two of an AFT024 cell, an MS5 cell, an OP9 cell, an HS-5 cell, an MSC cell, an MUTZ-3 cell, a stromal cell derived from tissues such as bone marrow or the liver, or a primary cell. Provided is the development of a brand-new method for inducing an NK cell on the basis of a CD34+ cell, which enables the induction of the NK cell with a high efficiency. The efficiency of outputting NK cells from a single CD34+ cell is improved, and the property of the induced NK cell is very close to that of a natural mature NK cell. They have uniform anti-tumor effects, can effectively kill tumor cells, and have broad application prospects.

There is provided a method of generating T cell lineage cells, the method comprising (a) culturing a sample comprising stem cells or progenitor cells with a soluble multispecific ligand comprising a Notch ligand and a functional protein partner (FPP) that binds to a surface molecule on the stem cells or progenitor cells, and (b) isolating the T cell lineage cells. In one embodiment, the T cell lineage cells are progenitor T cells or mature T cells. Multispecific ligands, compositions, kits and uses thereof are also provided.

The invention discloses a pancreatic beta cell precursor cell transplantation chip based on human-derived iPSC (induced pluripotent stem cell) as well as a preparation method and application of the pancreatic beta cell precursor cell transplantation chip. The chip is composed of beta cell precursor cells (expressing Pdx1, Nkx6.1 and NeuroD1) and a porous degradable bracket (PCL / hyaluronic acid composite material), wherein the beta cell precursor cells (expressing Pdx1, Nkx6.1 and NeuroD1) are obtained by performing four-stage induction on autologous iPSC. The preparation method comprises the steps of autologous iPSC acquisition, beta cell precursor cell induction, three-dimensional bracket preparation and chip assembly. After the chip is implanted into the pancreas of a patient through minimally invasive surgery, precursor cells are differentiated into mature beta cells in vivo, insulin is secreted, the stent is gradually degraded, the pancreas islet function can be fundamentally improved, and the chip is used for treating type I and type II diabetes mellitus. The invention avoids immunological rejection, improves cell survival and functional stability, and has significant clinical transformation value.

In an aspect, a method of making a humanized animal includes providing an immune-deficient animal lacking mature T cells, B cells and NK cells; and injecting a population of human thymocytes into the immune-deficient animal to provide the humanized animal; wherein the population of human thymocytes are thymocytes collected from human thymus or thymus tissue; and wherein the humanized animal includes mature human T cells expressing human CD8 and human CD4. In another aspect, also included is a humanized animal prepared by the foregoing method.

A gene delivery system and applications thereof in the technical field of biological medicines that is particularly useful in the preparation of drugs for treatment of tumors are disclosed. The gene delivery system and applications relate to technology for inducing the differentiation of malignant tumor cells into mature cells, in which regulating the expression of HNF4 alpha protein in the malignant tumor cells using messenger ribonucleic acid, the malignant phenotype of the malignant solid tumor cells is inhibited, and the effective treatment of the malignant solid tumors is achieved. The gene delivery system and applications are therefore applicable to a method of preparing a drug for treating malignant solid tumors and to a method of treating a patient having a malignant solid tumor.

The invention discloses an intelligent artificial bionic DC cell nanoparticle nDC-M and a preparation method, application and a detection method thereof. The nano-particle is of a core-shell structure, the inner core is a hypoxia response type nano-micelle of a sound-sensitive agent SP8 and IL-2 for activating T cells to be mature, the outer layer is coated with a mature DC cell membrane, and the nano-particle has the immune recognition characteristic and the treatment function. In a tumor hypoxic microenvironment, the micelle specifically releases SP8 and IL-2; sP8 generates ROS through ultrasonic excitation, tumor cell immunogenicity death is induced, and antigens are released; iL-2 activates proliferation and functions of tumor infiltration lymphocytes; the outer DC cell membrane and the antigen capture functional group enhance the collection and activation of immune cells through surface antigen presentation, and amplify the anti-tumor immune response. By combining sonodynamic therapy and immunoregulation, tumor growth is inhibited, metastatic load is reduced, good biocompatibility and safety are achieved, and a novel bionic delivery system is provided for metastatic tumor immune combined therapy.

A gene delivery system and applications thereof in the technical field of biological medicines that is particularly useful in the preparation of drugs for treatment of tumors are disclosed. The gene delivery system and applications relate to technology for inducing the differentiation of malignant tumor cells into mature cells, in which regulating the expression of HNF4 alpha protein in the malignant tumor cells using messenger ribonucleic acid, the malignant phenotype of the malignant solid tumor cells is inhibited, and the effective treatment of the malignant solid tumors is achieved. The gene delivery system and applications are therefore applicable to a method of preparing a drug for treating malignant solid tumors and to a method of treating a patient having a malignant solid tumor.

The invention discloses a method for obtaining, activating and amplifying natural killer cells through iPSC differentiation induction, and relates to the technical field of stem cell biology, the method for obtaining, activating and amplifying natural killer cells through iPSC differentiation induction comprises the following steps: S1, preparing and inoculating iPSC cells; s2, differentiating the iPSC to a mesoderm; s3, the mesoderm cells are differentiated to CD34 + hematopoietic endothelial cells; s4, differentiating the CD43 < + > / CD45 < + > hematopoietic stem cells into the iNK cells; s5, maturation of the iNK cells; s6, activating and amplifying the iNK cells; in the step S1, cells are resuspended by using a fresh E8 complete culture medium and are inoculated into a porous culture plate; a plurality of induction culture media are used in the culture process; by adopting a porous culture plate and using an E8 complete culture medium to resuspend cells, efficient inoculation and primary culture of iPSC are realized, and the survival rate and amplification efficiency of cells are improved; the differentiation process of the iPSC towards the mesoderm, the hematopoietic endothelial cells and the CD34 + hematopoietic stem cells is optimized by using various induction culture media, and the differentiation efficiency is improved.

The current invention provides for methods and systems of inducing cell cycle exit and terminal differentiation in stem cells undergoing differentiation into various mature cell types in particular pancreatic endocrine cells. The current invention also provides for methods and systems of inducing differentiation of pancreatic endocrine cells from stem cells. The invention also provides for the cells produced by the methods that are suitable for transplantation or grafting into a subject for the prevention and / or treatment of disease, and useful for basic research and drug testing.

This invention relates to the field of biotechnology, and proposes a method for sorting mature RPE cells from iPSC-differentiated cells and its applications. In this method, iPSCs are first induced to differentiate into mature RPE cells. Then, a combination of Papain and Accutase enzymes is used to gently and efficiently separate the cells into single-cell suspensions. A cell filter is then used to ensure that the cells are dispersed and appropriately sized single cells or small cell clusters. Finally, high-purity mature RPE cells are obtained through flow cytometry gating strategies and R780-H channel settings. This invention enables normal cell growth and rapid proliferation with minimal cell damage through a combination of enzymes; utilizes R780-H autofluorescence to improve sorting accuracy and reliability; allows for direct flow cytometry sorting after cell digestion and filtration, simplifying the operation, reducing cell damage, facilitating cell culture and expansion, and improving experimental efficiency; and sorts based on the cytochrome optical properties of mature RPE cells, eliminating the need for expensive antibody labeling, thus possessing significant application value.

A method of generating cells of the T cell lineage is provided comprising (a) culturing a sample comprising stem cells or progenitor cells with a Notch ligand conjugated to a suspension support and (b) isolating cells of the T cell lineage. In one embodiment, the cells of the T-cell lineage are progenitor T cells or mature T cells. Compositions, kits and uses thereof are also provided.

To provide methods, compositions, and kits for generating progenitor and mature T cells, and uses of the cells.SOLUTION: A method of generating cells of the T cell lineage is provided comprising: (a) culturing a sample comprising stem and progenitor cells with a Notch ligand conjugated to a suspension support; and (b) isolating cells of the T cell lineage. In one aspect, the cell of the T cell lineage is a primary T cell or a mature T cell. Compositions, kits, and uses of the cells are also provided.SELECTED DRAWING: Figure 1

A method of generating cells of the T cell lineage is provided comprising (a) culturing a sample comprising stem cells or progenitor cells with a Notch ligand conjugated to a suspension support and (b) isolating cells of the T cell lineage. In one embodiment, the cells of the T-cell lineage are progenitor T cells or mature T cells. Compositions, kits and uses thereof are also provided.

The invention discloses an immune-enhanced DC recruitment tumor nano vaccine and a preparation method and application thereof.The immune-enhanced DC recruitment tumor nano vaccine is obtained by combining tumor antigen, CCL20 and RADA16-I polypeptide to obtain tumor antigen gel, then adding a Ca < 2 + > solution and conducting extrusion through a filter membrane; the mass ratio of the tumor antigen to the CCL20 to the RADA16-I polypeptide is (175 to 225) to 1 to (110 to 140). The tumor nano vaccine can efficiently recruit DC cells, promote the DC cells to take more tumor antigens, promote the DC cells to be mature, enable the mature DC cells carrying the tumor antigens to migrate to lymph nodes to be presented to T cells and activate the T cells, and promote the number of the activated T cells in tumor tissues to be greatly increased, so that tumor growth can be obviously inhibited, and the tumor growth rate is increased. The composition has no obvious side effect on the body and has good biological safety.

The application discloses a method for simulating wood formation and radial growth of broad-leaved trees by using climate data and belongs to the technical field of tree growth prediction. In order to solve the problem of accurate simulation of wood formation and radial growth of broad-leaved trees, the application comprises the following steps: collecting input data including latitude data of a target region and long-term daily meteorological data of the target region; establishing cambium activation conditions of the broad-leaved trees; calculating relative growth rates of cell expansion, cell wall deposition and cambium cells, and calculating expansion rates of the cambium cells; establishing a cambium cell division model and a vessel cell differentiation cycle model; establishing a cell expansion model and a cell wall thickening model, simulating the growth process of the cells in the xylem until the cell wall lignification process is completed, and then the cells enter a mature cell stage; and based on the mature cell stage, calculating annual ring width and anatomical characteristics, and completing the simulation process of simulating the wood formation and radial growth of the broad-leaved trees by using the climate data.

The invention belongs to the technical field of biological medicine, and particularly relates to self-replicating RNA for expressing differentiation-related transcription factors and application of the self-replicating RNA in preparation of tumor treatment drugs. The invention relates to a technical means for inducing tumor cells to differentiate into mature cells, expression of important differentiation-related transcription factors in tumor cells is regulated by using messenger ribonucleic acid, malignant phenotypes of malignant solid tumor cells are inhibited, and the effect of treating malignant solid tumors is achieved, so that the messenger ribonucleic acid is applied to the preparation method and application of solid tumor drugs.

The application discloses application of MST1 interfering RNA in promoting in-vitro differentiation of ESCs into insulin-secreting cells, and belongs to the technical field of biotechnology. In the process of in-vitro directional differentiation of rat ESCs into beta cells, the application infects by using an MST1 shRNA lentivirus vector, and indexes are detected and functions are determined by using cell biology and molecular biology methods, and it is found for the first time that the efficiency of inducing ESCs to differentiate into beta cell-like cells can be improved by reducing the expression of MST1. Meanwhile, how MST1 realizes the regulation of beta cell maturation by means of PDX1 in the process of directional differentiation of rat ESCs into beta cells is described, the reason affecting in-vitro maturation of beta cells is discussed, and thus the system of directional differentiation of ESCs into mature beta cells is optimized, which has important significance for obtaining beta cells with normal insulin secretion function in-vitro.

[Problem] To provide a cell bank for quickly producing regenerative T cells having an antigen-specific T cell receptor of an individual introduced hereinto, said cell bank containing hematopoietic stem cells differentiated and induced from iPS cells, immature T cells and / or mature T cells as intermediates in the production. [Solution] A cell bank, which contains iPS cells and one or more kinds of cells selected from the group consisting of hematopoietic stem cells differentiated from iPS cells, immature T cells, and mature T cells is constructed. The iPS cells are obtained by initializing peripheral blood mononuclear cells from which B cells and T cells have been removed, or by initializing T cells. The T cell receptor gene is introduced into the hematopoietic stem cells or the immature T cells with the use of a viral vector, a transposon vector, or genome editing techniques. The T cell receptor gene is introduced into the mature T cells with the use of genome editing techniques.

New strategies for treating patients suffering from Parkinson's disease and other secondary Parkinson's conditions are disclosed. Disclosed are DA neuronal cells that have been modified in vitro with genetic insertion of GDNF. A GDNF coding sequence is inserted under transcriptional control of a promoter such that after the engineered cell that is to be administered has been mature to a neuronal mature cell type, secretory proteins are produced and uptake by endogenous cells to promote survival of the endogenous neurons. Also disclosed are DA neuronal cells that have been modified in vitro with genetic insertion of GBA and that are SNCA hemizygote-invalid. The GBA coding sequence is inserted under transcriptional control of a traversal promoter and produces secretory proteins after transplantation and uptake immediately by the implant and endogenous cells to promote long term implant integrity.